India caps mark-ups on cancer medicines after Supreme Court calls pricing 'extortion'
Following a 2022 legal challenge by a retired bank clerk, the Indian government will cut prices on 137 cancer drugs next month after the Supreme Court condemned excessive mark‑ups.

The Indian government has announced a reduction in the retail prices of cancer medicines after the Supreme Court ruled that certain mark‑ups by hospitals and pharmacists amounted to “extortion.” The change, prompted by a case first filed in 2022 by a retired bank clerk who could not afford her treatment, will bring lower prices for 137 cancer drugs starting next month.
The move aims to ease the financial burden on millions of patients who face severe hardship when diagnosed with cancer. Government officials said the revisions target high profits on some medicines charged by hospitals and dispensaries, a practice the court described in stark terms.
What the ruling and new caps mean
Under the government’s announcement, the price caps will apply to a list of 137 cancer medicines. The measures are intended to prevent patients from having to forgo treatment, sell assets such as land, or fall into debt to pay for necessary drugs — consequences cited in reporting about the decision. The Supreme Court’s finding that excessive mark‑ups constituted “extortion” was a central factor in prompting the policy response.
Origins of the case
The legal challenge began in 2022 when a retired bank clerk, unable to afford prescribed cancer therapy, brought the matter to the highest court. Reporting on the development attributes the subsequent government action directly to that petition and the court’s characterization of the pricing practices.
Why it matters
Advocates and observers have long raised concerns about the affordability of cancer treatment in India, where out‑of‑pocket costs can push families into financial crisis. By capping mark‑ups on a substantial set of oncology medicines, the government seeks to reduce those costs for a large number of patients nationwide. The change could alter pricing practices in hospitals and pharmacies that had been charging higher margins on certain cancer drugs.
Implementation and scope
According to reporting, the price reductions take effect from next month and cover the specified list of 137 medicines; details about enforcement, monitoring mechanisms or exact new price levels were not provided in the reports. The announcement follows the Supreme Court’s criticism of profit margins on some cancer drugs as unfairly high.
The government’s decision is being framed as a corrective step to protect patients from the severe economic consequences of expensive cancer care. Further information on the operational rollout and any challenges that arise as hospitals and pharmacies adjust their pricing was not included in the available reports.
Sources
This story was written from reports by these outlets. Read the originals:
- 1.Guardian Science: India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’
- 2.Guardian World: India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’
- 3.Guardian Business: India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’

